Illumina (ILMN) PT Raised to $330.00

Illumina (NASDAQ:ILMN) had its price target increased by stock analysts at Citigroup from $275.00 to $330.00 in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the life sciences company’s stock. Citigroup’s target price indicates a potential upside of 19.78% from the stock’s current price.

ILMN has been the subject of several other reports. Morgan Stanley raised their price target on shares of Illumina from $180.00 to $195.00 and gave the stock an “underweight” rating in a report on Thursday, May 31st. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, March 10th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a research note on Monday, April 16th. Barclays lifted their target price on shares of Illumina from $215.00 to $235.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 25th. Finally, ValuEngine cut shares of Illumina from a “buy” rating to a “hold” rating in a research note on Thursday, April 26th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company. Illumina currently has a consensus rating of “Buy” and an average target price of $256.42.

Shares of ILMN stock traded up $1.05 during trading on Monday, hitting $275.51. 4,329 shares of the company were exchanged, compared to its average volume of 730,702. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.41 and a current ratio of 2.71. The stock has a market cap of $41.55 billion, a P/E ratio of 69.93, a P/E/G ratio of 3.02 and a beta of 0.88. Illumina has a twelve month low of $167.98 and a twelve month high of $293.15.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.02 by $0.43. The business had revenue of $782.00 million during the quarter, compared to analysts’ expectations of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The firm’s quarterly revenue was up 30.8% compared to the same quarter last year. During the same period last year, the company posted $0.64 earnings per share. sell-side analysts predict that Illumina will post 4.86 EPS for the current year.

In other news, SVP Charles Dadswell sold 116 shares of the business’s stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $230.91, for a total value of $26,785.56. Following the completion of the sale, the senior vice president now directly owns 7,875 shares in the company, valued at $1,818,416.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mostafa Ronaghi sold 10,500 shares of the business’s stock in a transaction on Monday, June 11th. The stock was sold at an average price of $284.83, for a total transaction of $2,990,715.00. Following the completion of the sale, the senior vice president now owns 81,496 shares of the company’s stock, valued at $23,212,505.68. The disclosure for this sale can be found here. Insiders sold 39,271 shares of company stock valued at $10,483,503 over the last 90 days. 0.54% of the stock is owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Financial Gravity Companies Inc. bought a new position in Illumina during the fourth quarter worth $106,000. Harvest Fund Management Co. Ltd bought a new position in Illumina during the first quarter worth $113,000. Captrust Financial Advisors bought a new position in Illumina during the fourth quarter worth $165,000. Financial Gravity Wealth Inc. bought a new position in Illumina during the first quarter worth $193,000. Finally, Palladium Partners LLC bought a new position in Illumina during the first quarter worth $209,000. Institutional investors and hedge funds own 90.54% of the company’s stock.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply